A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1 (c2591) T Cells in HLA-A2+ Patients With Synovial Sarcoma
0-9 years 10-17 years 18-26 years
NY-ESO-1 (c259) T Cells
Condition: Synovial Sarcoma
The purpose of this early (pilot) clinical trial is to test the effects (both good and bad) of chemotherapy and adoptive immunotherapy with T cells engineered to recognize NY-ESO-1 peptide in patients with unresectable, metastatic or recurrent synovial sarcoma.